期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

氯吡格雷治疗后血小板高反应性研究现状 被引量：10

下载PDF
导出
摘要 氯吡格雷是目前冠状动脉支架术后抗血小板治疗的基石，在美国食品与药物管理局（FDA）批准普拉格雷之前，氯吡格雷是惟一被指南推荐使用的噻吩吡啶类抗血小板药物。然而，即使接受足量、长期的氯吡格雷治疗，部分患者仍有心脑血管血栓事件发生，谓之“氯吡格雷抵抗”。氯吡格雷抵抗关注于氯毗格雷对血小板活性的抑制情况，是用药前后对比的相对值，
作者 冷文修 范利
机构地区 解放军总医院南楼心血管二科
出处 《中华老年心脑血管病杂志》 CAS 北大核心 2013年第5期545-547,共3页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
关键词 血小板聚集抑制剂 血栓形成 血栓弹力描记术 多态性 单核苷酸
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献26

  • 1Gurbel PA, Becker RC, Mann KG, et al. Platelet function mo- nitoring in patients with coronary artery disease. J Am Coil Cardiol, 2007,50 : 1822-1834. 被引量：1
  • 2Breet NJ,van Werkum JW, Bouman H J, et al. Comparison of platelet function tests in predicting clinical outcome in pa- tients undergoing coronary stent implantation. JAMA, 2010, 303:754-762. 被引量：1
  • 3Price MJ,Angiolillo DJ,Teirstein PS, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary in- tervention:a time-dependent analysis of the gauging respon- siveness with a VerifyNow P2Y12 assay:impact on thrombosis and safety (gravitas) trial. Circulation,2011,124 : 1132-1137. 被引量：1
  • 4Campo G, Parrinello G, Ferraresi P, et al. Prospective evalua- tion of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol, 2011,57 : 247-2483. 被引量：1
  • 5Silvain J, Cayla G, Hulot JS, et al. High on thienopyridine platelet reactivity in elderly coronary patients the senior- platelet study. Eur Heart J, 2012,33 : 1241 -1249. 被引量：1
  • 6Ang L,Palakodeti V,Khalid A,et al. Elevated plasma fibrino- gen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coil Cardiol, 2008,52 : 1052-1059. 被引量：1
  • 7Morel O,E1 Ghannudi S,Jesel L,et al. Cardiovascular mortal ity in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Yz in- hibition by clopidogrel. J Am Coll Cardiol, 2011,57 : 399-408. 被引量：1
  • 8Leng WX,Ren JW,Cao J, et al. Chronic kidney disease-is it a true risk factor of reduced clopidogrel efficacy in elderly pa- tients with stable coronary artery disease? Thromb Res, 2013,131 : 218-224. 被引量：1
  • 9Linden MD, Tran H, Woods R, et al. High platelet reactivity and antiplatelet therapy resistance. Semin Thromb Hemost, 2012,38:200-212. 被引量：1
  • 10Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspi rin: the randomized, double blind OCLA (omeprazole clopi- dogrel aspirin) study. J Am Coil Cardiol, 2008,51 : 256-260. 被引量：1

同被引文献83

  • 1ANDREW L F,DEEPAK L B,RONALD D L,et al.Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms(CYP2C19,ABCB1,PON1),noncompliance,diet,smoking,co-medications(including proton pump inhibitors),and pre - existent variability in platelet function[J].J Am Coll Cardiol,2013,61(8):872-879. 被引量：1
  • 2SEREBRUANY Y L,STEINHUBL S R,BERGER PB,et al.Variability in platelet responsiveness to clopidogrela mong 544 individuals[J].J Am Coll Cardiol,2005,45(2):246-251. 被引量：1
  • 3BARSKY A A,ARORA R R.Clopidogrel resistance:myth or reality[J].J Cardiovasc Pharmacol Ther,2006,11(1):47-53. 被引量：1
  • 4GEORGE K,PERIKLIS D,IOANNA Xf et al.CYP2C19* 2 and other genetic variants affecting platelet response to clopidogrei in patients undergoing percutaneous coronary intervention[J].Thromb Res,2012,129(4):441-446. 被引量：1
  • 5GEISLER T,ZURN C,SIMONENKO R,et al.Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions[J].Eur Heart J,2010,31(1):59-66. 被引量：1
  • 6BARRAGAN P,BOUVIER J L,ROQUEBERT P O,et al.Resistance to thienopyridines:clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation[J].Catheter Cardiovasc Interv,2003,59(3):295-302. 被引量：1
  • 7SHULDINER A R,OfCONNELL J R,BLIDEN K P,et al.Asso-ciationof cytochrome P4502 C19 genotype with the antiplateleteffect and clinical efficacy of clopidogrei therapy[J].JAMA,2009,302(8):849-857. 被引量：1
  • 8US Food and Drug Adminitration.FDA drug safety communication:reduced effectiveness of Plavix(clopidogrei)in patients who are poor mebabolizers of the drug[EB/OL].[2010-03-12]http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyin-formationforpatientsandproviders/ucm203888.htm. 被引量：1
  • 9ISORDIA S I,OLALDE R M J,SANTIAGO G D,et al.The impact of CYP3A5*1/* 3,PIA1/A2 and T744C polymorphisms on clopidogrei and acetylsalicylic acid response variability in Mexican population[J].Thromb Res,2012,130(3):e67-e72. 被引量：1
  • 10Savi P,Herbert JM.Clopidogrel and ticlopidine:P2Y12adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis[J].Semin Thromb Hemost,2005,31(2):174-183. 被引量：1

引证文献10

二级引证文献47

中华老年心脑血管病杂志
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部